JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2025. Vol. 70. № 2
DOI:10.33266/1024-6177-2025-70-2-81-87
P.V. Sychev1, Yu.D. Udalov1, 2, E.V. Mayakova1, Yu.A. Kaidash1, M.I. Shcherbakov1, I.A. Baryshnikov1
Epidemiological Analysis of Thyroid Cancer in the System of FMBA of Russia
1 Federal Scientific Clinical Center for Medical Radiology and Oncology, Dimitrovgrad, Russia
2 A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Petr Vladimirovich Sychev, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: According to statistical data for 2022, thyroid cancer (TC) is in 3rd place in terms of detection frequency (9.4 %) in people under 30 years of age. At the same time, the frequency of malignant neoplasms (MNT) of the thyroid gland in young women from 0 to 29 years old is 13.6 %, which is more than the frequency of cervical cancer (8.4 %) [1]. According to the register of cancer patients of the Volga Federal District in 2022, the number of patients with cancer of the thyroid gland registered in oncology institutions with a diagnosis of cancer for the first time in their life is 2,231 people. By the end of this year, 20,908 patients had been registered for 5 years or more; mortality averaged 0.5 %.
The above circumstances dictate the need to find ways to improve the results of radioiodine therapy for thyroid cancer based on its timely diagnosis, prevention of secondary resistance and optimization of treatment tactics. This became the prerequisites for the development of a modern tool for epidemiological analysis of the results of the use of radionuclide therapy 131I in the treatment of thyroid cancer in the FMBA system of Russia and the implementation of applied research work according to the State assignment.
Material and methods: Over the course of a year and a half of research, data on radioiodine therapy for thyroid cancer at the Nuclear Medicine Centers of the Federal Medical and Biological Agency of Russia were studied for more than 900 patients from various regions of the Russian Federation. The necessary medical documentation of these patients was studied, data was generated, subjected to epidemiological analysis and entered into an electronic database.
Results: The study analyzed the criteria that most optimally reflect the patient’s condition upon admission, treatment parameters and indicators of its effectiveness. The result of this work is to optimize treatment parameters, which will allow us to determine a personalized approach to radionuclide therapy with 131I in the treatment of thyroid cancer.
Keywords: thyroid cancer, epidemiology, radioiodine therapy, 131I
For citation: Sychev PV, Udalov YuD, Mayakova EV, Kaidash YuA, Shcherbakov MI, Baryshnikov IA. Epidemiological Analysis of Thyroid Cancer in the System of FMBA of Russia. Medical Radiology and Radiation Safety. 2025;70(2):81–87. (In Russian). DOI:10.33266/1024-6177-2025-70-2-81-87
References
1. Zlokachestvennyye Novoobrazovaniya v Rossii v 2021 godu (Zabolevayemost’ i Smertnost’ = Malignant Neoplasms in Russia in 2021 (Morbidity and Mortality). Ed. A.D.Kaprin, V.V.Starinskiy, A.O. Shakhzadova. Moscow, MNIOI imeni P.A. Gertsena - branch of the National Medical Research Center of Radiology of the Ministry of Health of Russia Publ., 2022. 252 p. (In Russ.).
2. Volkova N.I., Merenkova M.D. Errors in the Treatment of Well-Differentiated Thyroid Cancer as an Interdisciplinary Problem. Meditsinskiy Vestnik Yuga Rossii = Medical Bulletin of the South of Russia. 2021;12;2:92-95 (In Russ.). doi: 10.21886/22198075-2021-12-2-92-95.
3. Dedov I.I. Endokrinologiya: Natsional’noye Rukovodstvo = Endocrinology: National Guide. Ed. I.I.Dedov, G.A.Melnichenko. Moscow: GEOTAR-Media Publ., 2019. 1112 p. (In Russ.). ISBN 978-5-9704-5083-3.
4. Thyroid Cancers Glenn D. MSD Manual Professional Version. Braunstein. URL: https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/thyroid-disorders/thyroid-cancers.
5. Matyakin E.G., Podvyaznikov S.O. Opukholi Shchitovidnoy Zhelezy. Onkologiya: Spravochnik Praktikuyushchego Vracha = Tumors of the Thyroid Gland. Oncology. A Practitioner’s Handbook. Ed. I.V.Poddubnyy. Moscow, MEDpress-inform Publ., 2009. Pp. 177–185 (In Russ.).
6. Beltsevich D.G., Vanushko V.E., Rumyantsev P.O., et al. Russian Clinical Guidelines for the Diagnosis and Treatment of Well-Differentiated Thyroid Cancer in Adults, 2017. Endokrinnaya Khirurgiya = Endocrine Surgery. 2017;11;1:6-27 (In Russ.). doi: 10.14341/serg201716-27.
7. Differentsirovannyy Rak Shchitovidnoy Zhelezy = Differentiated Thyroid Cancer. Clinical Recommendations of the Ministry of Health of the Russian Federation. 2020. 47 p. (In Russ.).
8. Beltsevich D.G., Vanushko V.E., Melnichenko G.A., et al. Clinical Recommendations of The Russian Association of Endocrinologists for the Diagnosis and Treatment of Multi-Nodular Goiter in Adults (2015). Endokrinnaya Khirurgiya = Endocrine Surgery. 2016;10;1:5–12 (In Russ.). doi: 10.14341/serg201615-12. EDN WELZCF.
9. Demidova T.Yu., Drozdova I.N., Potekhin N.P., Orlov F.A. Principles of Diagnosis and Treatment of Nodular Goiter. Meditsinskiy sovet = Medical Council. 2016;3 (In Russ.). URL: https://cyberleninka.ru/article/n/printsipy-diagnostiki-i-lecheniya-uzlovogo-zoba (date of access: 28.08.2024).
10. Alexander E.K., Cooper D. The Importance, and Important Limitations, of Ultrasound Imaging for Evaluating Thyroid Nodules. JAMA Intern Med. 2013;173;19:1796-1797. doi:10.1001/jamainternmed.2013.8278.
11. Danese D., Sciacchitano S., Farsetti A., Andreoli M., Pontecorvi A. Diagnostic Accuracy of Conventional Versus Sonography-Guided Fine-Needle Aspiration Biopsy of Thyroid Nodules. Thyroid. 1998;8;1:15-21. URL: http://www.ncbi.nlm.nih.gov/pubmed/24205031. doi:10.1089/thy.1998.8.15.
12. Russ G., Bonnema S.J., Erdogan M.F., Durante C., Ngu R., Leenhardt L. European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: the EU-TIRADS. Eur Thyroid J. 2017 Sep; 6;5:225-237. doi: 10.1159/000478927. Epub 2017 Aug 8. PMID: 29167761; PMCID: PMC5652895.
13. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2006;16;2:109–142. doi:10.1089/thy.2006.16.109.
14. Vuong H.G., Altibi A.M.A., Duong U.N.P., Hassell L. Prognostic Implication of BRAF and TERT Promoter Mutation Combination in Papillary Thyroid Carcinoma - a Metaanalysis. Clin Endocrinol (Oxf). 2017;87;5:411–417. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28666074. doi:10.1111/cen.13413.
15. Geliashvili T.M., Vazhenin A.V., Afanasyeva N.G. Basics of the Use of Combined Positron Emission and Computed Tomography with 18-Fluorodeoxyglucose in Differentiated Thyroid Cancer after Primary Treatmen. Opukholi Golovy i Shei = Head and Neck Tumors. 2017;1 (In Russ.). URL: https://cyberleninka.ru/article/n/osnovy-primeneniya-sovmeschennoy-pozitronno-emissionnoy-i-kompyuternoy-tomografii-s-18-ftordezoksiglyukozoy-pri-differentsirovannom (date of access: 03.03.2023).
16. Feine U., Lietzenmayer R., Hanke J.P., Held J., Wöhrle H., Müller-Schauenburg W. Fluorine-18-FDG and Iodine-131-Iodide Uptake in Thyroid Cancer. J Nucl Med. 1996;37;9:1468-1472.
17. Odzharova A.A., Dolgushin M.B., Mudunov A.M., Romanov I.S., Tulin P.E., Nevzorov D.I. Combined Positron Emission and Computed Tomography with 18f-Fluorodeoxyglucose in Assessing the Effectiveness of Targeted Therapy for Radioiodine-Resistant Well-Differentiated Thyroid Cancer (Clinical Observation). Opukholi Golovy i Shei = Tumors of the Head and Neck. 2017;7;3:103-107 (In Russ.). doi: 10.17650/2222-1468-2017-7-3-103-107.
18. Geliashvili T.M., Vazhenin A.V., Yaytsev S.V., Vasilyeva E.B. The Role of Post-Therapeutic Whole Body Scintigraphy with I-131 during a Course of Radioiodine Ablation in the Management of Patients with Differentiated Thyroid Cancer. Tavricheskiy Mediko-Biologicheskiy Vestnik = Tauride Medical and Biological Bulletin. 2017;20;3:68–73 (In Russ.). URL: https://cyberleninka.ru/article/n/rol-postterapevticheskoy-stsintigrafii-vsego-tela-s-i-131-na-kurse-radioyodablatsii-v-vedenii-bolnyh-differentsirovannym-rakom.
19. Luster M., Clarke S.E., Dietlein M., et al. Guidelines for Radioiodine Therapy of Differentiated Thyroid Cancer. Eur J Nucl Med Mol Imaging. 2008;35;10:1941–1959. doi:10.1007/s00259-008-0883-1.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The work was performed within the framework of the state assignment of the FMBA of the Russia registration No. R&D 1022060300090-7-3.2.21.
Contribution. Article was prepared with equal participation of the authors.
Article received: 20.12.2024. Accepted for publication: 25.01.2025.